Molecular Partners Receives Shareholder Approval at AGM
Molecular Partners AG, a clinical-stage biotech enterprise renowned for its pioneering DARPin therapeutics, is excited to share that at its recent Annual General Meeting, all proposals put forth by the Board of Directors received overwhelming shareholder approval. This gathering, hosted in Zurich, not only reaffirms shareholder confidence but also bolsters the company’s strategic direction.
Financial Review and Future Outlook
During the meeting, shareholders ratified the annual review along with the IFRS consolidated financial statements for the fiscal year. The approval included a consultative vote on the compensation report and a pivotal decision on the net loss for the year. The carried forward loss has been updated to CHF 199,440,147, indicating a thoughtful approach to the company's financial strategy as they navigate future challenges.
Leadership Retention and Assurance
The shareholders granted discharge to the Board and Management for their actions over the past financial year. The reaffirmation of leadership was evident with the re-election of William “Bill” Burns as Chairman and the continued engagement of Steven Holtzman and Michael Vasconcelles, M.D., in the pivotal Nomination and Compensation Committee, ensuring stability and continuity in governance.
Stewardship by KPMG and New Proxy Oversight
In a bid to maintain rigorous oversight, KPMG AG Zurich was re-elected as the company’s statutory auditors for the upcoming fiscal year, which is crucial for maintaining investor trust. In addition, Anwaltskanzlei Keller AG from Zurich has been appointed as the independent proxy, a strategic move geared towards strengthening corporate governance until the next Annual General Meeting.
Commitment to Compensation Equity
An important part of the meeting involved the approval of all proposed compensation structures for both the Board and Management. This demonstrates Molecular Partners' commitment to aligning incentives with shareholder interests, ensuring that leaders are rewarded for successful outcomes.
About Molecular Partners AG
Molecular Partners AG is at the forefront of developing innovative DARPin therapeutics aimed at addressing unmet medical needs where traditional therapies fall short. With extensive programs in various phases of clinical development, the company’s primary focus lies within oncology. Founded in 2004, Molecular Partners not only operates from Zurich but also has a significant presence in Concord, Massachusetts, USA. The synergy between these locations enhances their research capabilities and collaborative opportunities with industry partners.
Contact Information for Inquiries
For further inquiries regarding Molecular Partners and its initiatives, individuals may contact Seth Lewis, the Senior Vice President of Investor Relations & Strategy, situated in Concord, Massachusetts, U.S. He can be reached at +1 781 420 2361 or via email at seth.lewis@molecularpartners.com. Alternatively, Laura Jeanbart, PhD, who oversees Portfolio Management & Communications in Zurich, is also available for inquiries at +41 44 575 19 35 or laura.jeanbart@molecularpartners.com.
Frequently Asked Questions
What was the outcome of the Annual General Meeting?
The Annual General Meeting yielded positive responses with all board proposals being approved by a significant majority of shareholders.
Who was re-elected as Chairman of the Board?
William “Bill” Burns was re-elected as Chairman of the Board, reaffirming his vital role in the company’s leadership.
What was the financial focus of the AGM?
The meeting emphasized the approval of the financial statements and the strategic decision to carry forward the company's net loss from the past financial year.
What measures are in place for corporate governance?
KPMG AG Zurich was re-elected as statutory auditors, and Anwaltskanzlei Keller AG was appointed as the independent proxy, ensuring strong governance.
How can I reach out to Molecular Partners for more information?
Individuals can contact Seth Lewis or Laura Jeanbart via the provided contact information for any inquiries regarding the company.
